ASCO 2018: OPTIMISMM Trial Results of Pomalidomide Triplet in Resistant Myeloma
Posted: Thursday, June 7, 2018
Patients with relapsed or refractory multiple myeloma who previously received lenalidomide and then were given the triplet regimen of pomalidomide, bortezomib, and low-dose dexamethasone (PVd) experienced significant progression-free survival benefit, versus bortezomib and low-dose dexamethasone alone (Vd), with no new safety concerns. The international phase III OPTIMISMM trial compared PVd and Vd in 559 patients, 100% of whom were exposed to lenalidomide and about 70% of whom had lenalidomide-refractory disease. Paul G. Richardson, MD, of Dana-Farber Cancer Institute, Boston, presented the final progression-free survival and safety data at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting (Abstract 8001).
“After a median follow-up of 16 months, PVd significantly reduced the risk of progression or death by 39% versus Vd,” noted the investigators. The median progression-free survival times for the PVd (n = 281) and Vd (n = 278) arms were 11.20 and 7.10 months, respectively. As for overall survival, the data are not yet mature.
Although the median number of previous treatments in each study arm was two, “40% in the PVd arm and 41% in the Vd arm had [only] one prior treatment line,” the team wrote. For that subgroup, the median progression-free survival was 20.73 months with PVd, compared with 11.63 months with Vd, for a reduction of risk of 46%.
“There remains an unmet medical need for those patients who have received lenalidomide-based therapies and are in early relapse,” stated Dr. Richardson in a Dana-Farber press release. “Pomalidomide-bortezomib-dexamethasone provides a new therapeutic platform for yet further treatment advances such as the incorporation of monoclonal antibodies.”
